Evan Lipson, MD, an associate professor of oncology at John Hopkins School of Medicine and a head and neck oncologist at John Hopkins Medicine, discusses the evolving treatment landscape for advanced melanoma.
2025
Dabrafenib-Trametinib Combo Shows Activity as Second-Line Adjuvant Therapy in Advanced Melanoma
Second-line adjuvant treatment with dabrafenib and trametinib appeared effective in a small study of patients with BRAF V600-mutated, resected, stage III/IV melanoma, researchers found. In fact, more than 80% of patients were free from relapse and metastasis at 1 year. These results were published in The Oncologist.
Study identifies ‘turncoat’ cells that fight—and aid—cancer
Yale researchers have made an unexpected discovery—turncoat T cells that help a tumor evade other cancer-fighting immune T cells—in a study of patients living with advanced melanoma.
FDA Grants Fast Track Designation to LBS-007 in AML
LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.